Companies › Beijing VDJBio
2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 3; Immunology, Oncology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VDJ001 IL-6 receptor antagonist monoclonal antibody | IL6R | Phase 3 | Anti IL-6R | Jun 2027 |
| Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection anti-IL-6 receptor monoclonal antibody | IL6R | Phase 2 | Idiopathic Multicentric Castleman's Disease | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05345522 | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection | Phase 2 | Idiopathic Multicentric Castleman's Disease | Immunology | Nov 2022 |
| NCT07872423 | VDJ001 | Phase 3 | Anti IL-6R | Oncology | Jun 2027 |
Roche Biocad Johnson & Johnson (Janssen) Innovent Biologics (Suzhou) Sanofi R-Pharm Kodiak Sciences
Tanabe Pharma Taizhou Mabtech Pharmaceutical RAPT Therapeutics, Inc., a member of the GSK plc group of companies CrystalGenomics Partner Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.